Clinical trial NCT01791985: AZD4547 & Anastrozole or Letrozole (NSAIs) in ER+ Breast Cancer Patients Who Have Progressed on NSAIs (RADICAL)
Official title: A Single Arm Phase IIa Study (With Combination SRI) to Assess the Safety & Efficacy of AZD4547 in Combination With Either Anastrozole or Letrozole in ER+ Breast Cancer Patients Who Have Progressed on Treatment With Anastrozole or Letrozole
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Breast Cancer
Keywords: Breast Cancer
AZD4547
Safety Run-In
FGFR1
ER positive breast cancer
Single arm phase IIa study
Lead sponsor: Imperial College London
Sponsor class: OTHER
Collaborators: name: Cancer Research UK
name: AstraZeneca
First posted: 2013-02-15
Enrollment: 52
Sex: FEMALE
Minimum age (years): 25
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is looking at a new drug called AZD4547 which is being tested for the treatment of oestrogen receptor positive breast cancer. AZD4547 is a drug which specifically "blocks" proteins called fibroblast growth factor receptors (FGFR1) that are involved in the processes that help cancer cells to grow. These proteins may also be responsible for the development of resistance to hormonal therapies used to treat some breast cancers. AZD4547 is not yet approved for use in breast cancer and is therefore being used in this study as a research drug.

The investigators will also test the theory that it is not necessary for high levels of FGFR1 to be present in the body to see benefit from AZD4547. (Stage 1 only)

Detailed description: The study will be carried out in two stages. Stage 1 is to find a suitable dose of AZD4547 which can be used together with a class of drugs called nonsteroidal aromatase inhibitors (e.g. anastrozole or letrozole) i.e. a dose which does not cause too many unacceptable side effects.

Patients with hormone sensitive (oestrogen receptor positive) breast cancer, whose current treatment with anastrozole or letrozole has recently stopped working properly will be eligible for this stage.

Stage 2 will then assess the efficacy of AZD4547, based on the change in tumour size at 12 weeks (or progression if prior to week 12), when used in combination with either anastrozole or letrozole in patients with hormone sensitive (oestrogen receptor positive) breast cancer, who have progressed on treatment with either anastrozole or letrozole in any setting.

In both stages, the study will look at how well the new treatment is tolerated.

Each patient is only allowed to take part in either stage 1 or 2.

The study will be run in 9 Hospitals across England and Scotland.

Eligibility criteria: Inclusion Criteria Patients must fulfil all of the following criteria.

1. Written (signed and dated) informed consent and be capable of co-operating with treatment and follow-up
2. Aged ≥ 25 years of age (N.B. in line with other studies with AZD4574 and due to concerns of possible effects on the immature skeleton)
3. Post menopausal women. Women will be considered postmenopausal if they have had a bilateral oophorectomy or the following specific requirements apply:

   Safety run-in:
   * Women under 50 years old would be considered post-menopausal if they have been amenorrhoeic for 24 months and have follicle-stimulating hormone (FSH) and oestradiol levels in the post-menopausal range. Patients with prior exposure to depot Luteininzing hormone releasing hormones (LHRH) analogues must be 24 months or more following the last administration
   * Women aged 50 years and older would be considered post-menopausal if they have been amenorrhoeic for 12 months and patients with prior exposure to depot LHRH analogues must be 12 months or more following the last administration
   * Women rendered amenorrhoeic by adjuvant chemotherapy, who were premenopausal or perimenopausal prior to chemotherapy, must have been amenorrhoeic for at least 24 months

   Phase IIa:
   * Women under 50 years old would be considered post-menopausal if they have been amenorrhoeic for 24 months and have follicle-stimulating hormone (FSH) and oestradiol levels in the post-menopausal range.
   * Women aged 50 years and older would be considered post-menopausal if they have been amenorrhoeic for 12 months
   * Women rendered amenorrhoeic by adjuvant chemotherapy, who were premenopausal or perimenopausal prior to chemotherapy, must have been amenorrhoeic for at least 24 months
   * Perimenopausal women rendered amenorrhoeic from exposure to depot LHRH analogues\*

     * Patients must have taken LHRH analogues for at least 6 months
4. Eastern Cooperative Oncology Group (ECOG) performance status 0-1 with no deterioration over the previous 2 weeks and minimum life expectancy of 12 weeks
5. Histological confirmation of breast cancer with documented positive oestrogen receptor status (ER+) of primary or metastatic tumour tissue according to local laboratory parameters
6. Phase IIa: Mandatory provision of tumour biopsy for assessment of oncology biomarkers
7. Fulfils criteria for previous treatment of breast cancer\*:

   Safety run-in:
   * Relapse during a single regimen of adjuvant endocrine therapy with either anastrozole or letrozole or
   * Progression during first line endocrine therapy with a non-steroidal Aromatase Inhibitor (AI) for advanced breast cancer\*\*. Co-administration of a targeted agent with the non-steroidal AI is permitted providing all toxicities have recovered to CTCAE Grade 1 or below 1 prior regimen of chemotherapy in the advanced setting is permitted. Chemotherapy administered in the adjuvant setting is permitted

   Phase IIa:

   o Progressing or progression at some point during breast cancer treatment on endocrine therapy with a non-steroidal AI.\*\*\* Co-administration of a targeted agent with the non-steroidal AI is permitted providing all toxicities have recovered to CTCAE Grade 1 or below.
   * Prior chemotherapy in the advanced and adjuvant setting is permitted.
   * Prior treatment with exemestane with or without everolimus is permitted.

     * Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer patients should have been offered at least one prior line of HER2 directed therapy \*\*Advanced breast cancer: metastatic disease or locally advanced disease which is not amenable to treatment with curative intent \*\*\*anastrozole or letrozole does not have to be the most recent therapy
8. Safety run-in: At least one lesion (measurable and/or non-measurable) that can be accurately assessed by CT/MRI/plain x-ray at baseline and follow up visits Phase IIa: At least one lesion ≥ 10mm in the longest diameter at baseline (or ≥ 15mm in the short axis for nodal disease) that can be accurately measured with CT/MRI at baseline and is suitable for accurate repeated measurements. Patients with bone only metastatic cancer must have a lytic or mixed lytic-blastic lesion that can be accurately assessed by CT or MRI.
9. Safety run-in: Study entry must be preceded by a minimum of 21 days of anastrozole or letrozole treatment Phase IIa: No set duration of anastrozole or letrozole treatment prior to study entry.

Exclusion Criteria

1. Treatment with any of the following:

   1. Safety run-in: more than 1 regimen of endocrine therapy for advanced breast cancer
   2. previous exposure to any FGFR inhibitor
   3. Safety run in: more than 1 prior regimen of chemotherapy for advanced breast cancer.
   4. potent inhibitors or inducers of CYP3A4 or CYP2D6, or substrates of CYP3A4 within 2 weeks prior to first dose of study treatment (3 weeks for St John's Wort)
   5. major surgery within 4 weeks prior to first dose of study treatment
   6. radiotherapy with a wide field of radiation within 4 weeks prior to first dose of study treatment; or radiotherapy with a limited field of radiation for palliation within 2 weeks before the first dose of study treatment
2. With the exception of alopecia, any unresolved toxicities from prior therapy greater than CTCAE grade 1 at time of starting study
3. Spinal cord compression or brain metastases unless asymptomatic, treated and stable and not requiring steroids for at least 4 weeks prior to start of study treatment
4. Any evidence of severe or uncontrolled systemic diseases or active infection
5. Any of the following cardiac criteria:

   1. Resting corrected QT interval (QTc) \>470 ms
   2. Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG e.g. complete left bundle branch block, third degree heart block
   3. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age or any concomitant medication known to prolong the QT interval
6. Inadequate bone marrow reserve or organ function as defined by any one of the following parameters:

   Haemoglobin \< 9.0 g/dL (\<90.0 g/L) Absolute neutrophil count (ANC) \< 1.5 x 109 /L Platelet count \< 100 x 109 /L Alanine aminotransferase \> 2.5 x Upper Limit of Normal (ULN) if no demonstrable liver metastases or \> 5 x ULN in the presence of liver metastases Aspartate aminotransferase \> 2.5 x ULN if no demonstrable liver metastases or \> 5 x ULN in the presence of liver metastases Total bilirubin \> 1.5 x ULN if no demonstrable liver metastases or \> 3 x ULN in the presence of liver metastases Creatinine \> 1.5 times ULN or creatinine clearance \<50ml/min Corrected calcium \> ULN Phosphate \> ULN
7. Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated Investigational Medicinal Product (IMP) or previous significant bowel resection that would preclude absorption of AZD4547 or anastrozole or letrozole
8. History of hypersensitivity to anastrozole or letrozole
9. History of another malignancy within 5 yrs prior to starting study treatment, except adequately treated basal or squamous cell carcinoma of the skin, carcinoma of the cervix and the disease under study
10. Any of the following ophthalmological criteria:\*

    * Current evidence or previous history of retinal pigmented epithelium detachment (RPED)
    * Previous laser treatment or intra-ocular injection for treatment of macular degeneration
    * Current evidence or previous history of soft drusen, drusenoid RPE detachment and wet macular degeneration.
    * Current evidence or previous history of retinal vein occlusion (RVO)
    * Current evidence or previous history of retinal degenerative diseases (e.g. hereditary) \*Patients with uncontrolled glaucoma or intra-ocular pressure \>21 mmHg at screening should be referred for ophthalmological management and the condition controlled prior to first dose of study treatment.
11. Concurrent treatment with another investigational agent or use of another investigational agent within 30 days or 5 half lives, whichever is longer, preceding the first dose of study treatment
12. Concurrent treatment with prohibited medications and wash out period for that drug will not have been completed before starting study medication

Primary outcomes:
measure: Number of Participants With Serious Adverse Events (SAEs)
timeFrame: Dose limiting toxicity (DLT) assessment window - days 1 to 28 of cycle 1
measure: Proportion of Tumour Size Change at 12 Weeks (or Progression if Prior to Week 12)
timeFrame: 12 weeks
Secondary outcomes:
measure: Proportion of Tumour Size Change at 6, 20 and 28 Weeks
timeFrame: 6, 20 and 28 weeks
measure: Tumour Response (RECIST Criteria) at 6, 12, 20 and 28 Weeks
timeFrame: 6, 12, 20 and 28 weeks
measure: Objective Response at 6, 12, 20 and 28 Weeks
timeFrame: 6, 12, 20 and 28 weeks
measure: Progression Free Survival
timeFrame: 42 months
Other outcomes:
Locations:
city: Burton-on-Trent
country: United Kingdom
facility: Queen's Hospital, Burton-on-Trent
state: Staffs
city: Dudley
country: United Kingdom
facility: Russells Hall Hospital, West C8 Admin Office, 2nd Floor
state: West Midlands
city: Cambridge
country: United Kingdom
facility: Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Breast Cancer Research Unit, PO Box 97, Hills Road,
city: Glasgow
country: United Kingdom
facility: Greater Glasgow Health Board, Beatson West of Scotland Cancer Centre, 1053 Great Western Road,
city: London
country: United Kingdom
facility: Imperial College Healthcare NHS Trust, Charing Cross Hospital,1st Floor, Department of Medical Oncology, Fulham Palace Road
city: Manchester
country: United Kingdom
facility: The Christie NHS Foundation Trust, Wilmslow Road, Withington
city: Newcastle upon Tyne
country: United Kingdom
facility: The Newcastle upon Tyne Hospitals NHS Foundation Trust, Sir Bobby Robson Cancer Trials Research Centre, Freeman Hospital, High Heaton
Study officials:
affiliation: Imperial College Healthcare NHS Trust
name: Michael Seckl
role: PRINCIPAL_INVESTIGATOR
affiliation: Newcastle-upon-Tyne Hospitals NHS Trust
name: Nicola Cresti
role: PRINCIPAL_INVESTIGATOR
affiliation: Cambridge University Hospitals NHS Foundation Trust
name: Richard Baird
role: PRINCIPAL_INVESTIGATOR
affiliation: NHS Greater Glasgow and Clyde
name: Iain MacPherson
role: PRINCIPAL_INVESTIGATOR
affiliation: Poole Hospital NHS Foundation Trust
name: Amitabha Chakrabarti
role: PRINCIPAL_INVESTIGATOR
affiliation: Burton Hospitals NHS Foundation Trust
name: Mojca Persic
role: PRINCIPAL_INVESTIGATOR
affiliation: The Christie NHS Foundation Trust
name: Anne Armstrong
role: PRINCIPAL_INVESTIGATOR
affiliation: The Dudley Group NHS Foundation Trust
name: Rozenn Allerton
role: PRINCIPAL_INVESTIGATOR
References:
citation: Coombes RC, Badman PD, Lozano-Kuehne JP, Liu X, Macpherson IR, Zubairi I, Baird RD, Rosenfeld N, Garcia-Corbacho J, Cresti N, Plummer R, Armstrong A, Allerton R, Landers D, Nicholas H, McLellan L, Lim A, Mouliere F, Pardo OE, Ferguson V, Seckl MJ. Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer. Nat Commun. 2022 Jun 10;13(1):3246. doi: 10.1038/s41467-022-30666-0.